**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: February 12, 1980
* Admit Date: March 10, 2023
* Discharge Date: March 15, 2023

**Medical History:**

John Doe was admitted to the endocrinology unit on March 10, 2023, with complaints of increased thirst and urination. He had a past medical history of hypertension and hyperlipidemia, for which he was taking medication.

**Clinical Course:**

Upon admission, John Doe's fasting plasma glucose (FPG) level was 220 mg/dL, and his glycosylated hemoglobin (HbA1C) level was 8.2%. He was diagnosed with type 2 diabetes mellitus based on these values. A random glucose value of 240 mg/dL was also obtained, which further supported the diagnosis.

**Diagnostic Workup:**

A complete blood count (CBC), comprehensive metabolic panel (CMP), and lipid profile were performed. The results showed mild anemia, elevated creatinine levels, and dyslipidemia. A foot examination revealed mild sensory loss in the right foot, and a funduscopic examination showed mild non-proliferative diabetic retinopathy.

**Treatment and Management:**

John Doe was started on metformin 500 mg twice daily, and his blood glucose levels were monitored regularly. He was also prescribed a GLP-1 receptor agonist, semaglutide 2.4 mg once weekly, for weight loss and improved glucose control. His hypertension and hyperlipidemia were managed with ongoing medications.

**Patient Education:**

John Doe received detailed education on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications. He was also educated on adjusting insulin doses based on blood glucose levels and carbohydrate intake. He was advised to maintain a healthy diet, focusing on whole foods and high-quality carbohydrates, and to engage in physical activity for at least 150 minutes per week.

**Discharge Instructions:**

John Doe was discharged on March 15, 2023, with the following instructions:

* Continue metformin 500 mg twice daily and semaglutide 2.4 mg once weekly.
* Monitor blood glucose levels regularly and adjust insulin doses as needed.
* Engage in physical activity for at least 150 minutes per week, with adjustments for hypoglycemia risk.
* Monitor for signs and symptoms of hypoglycemia and hyperglycemia, and seek medical attention if symptoms occur.
* Follow up with his primary care physician in one week for further monitoring and adjustment of medication as needed.

**Future Care:**

John Doe will be followed up with his primary care physician for regular monitoring of his blood glucose levels, blood pressure, and lipid profile. He will also be referred to a podiatrist for regular foot care and to a registered dietitian for nutrition counseling.

**Conclusion:**

John Doe was diagnosed with type 2 diabetes mellitus and was treated with metformin and a GLP-1 receptor agonist. He received detailed education on diabetes management and was discharged with instructions for ongoing care. He will require regular follow-up with his primary care physician to monitor his condition and adjust his treatment plan as needed.